Healthcare provider profile · identity verified

Silke Krieger, MD

Internal Medicine · JAMAICA PLAIN, MA · NPI 1356306773

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	426	137
Amlodipine Besylate	Amlodipine Besylate	370	105
Losartan Potassium	Losartan Potassium	197	66
Lisinopril	Lisinopril	190	57
Metoprolol Succinate	Metoprolol Succinate	187	52
Levothyroxine Sodium	Levothyroxine Sodium	143	45
Omeprazole	Omeprazole	138	48
Rosuvastatin Calcium	Rosuvastatin Calcium	135	35
Simvastatin	Simvastatin	105	31
Metformin Hcl	Metformin Hcl	103	32
Hydrochlorothiazide	Hydrochlorothiazide	102	32
Eliquis	Apixaban	91	23
Gabapentin	Gabapentin	91	33
Furosemide	Furosemide	82	20
Famotidine	Famotidine	79	29
Metformin Hcl Er	Metformin Hcl	67	24
Fluticasone Propionate	Fluticasone Propionate	61	24
Spironolactone	Spironolactone	59	17
Alprazolam	Alprazolam	57	suppressed
Jardiance	Empagliflozin	55	16
Albuterol Sulfate Hfa	Albuterol Sulfate	54	24
Allopurinol	Allopurinol	54	15
Trazodone Hcl	Trazodone Hcl	53	17
Oxycodone Hcl	Oxycodone Hcl	50	11
Trulicity	Dulaglutide	49	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	48	18
Atenolol	Atenolol	47	14
Ezetimibe	Ezetimibe	47	17
Pantoprazole Sodium	Pantoprazole Sodium	44	21
Sertraline Hcl	Sertraline Hcl	43	15
Donepezil Hcl	Donepezil Hcl	42	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	42	suppressed
Potassium Chloride	Potassium Chloride	42	16
Tramadol Hcl	Tramadol Hcl	38	12
Duloxetine Hcl	Duloxetine Hcl	35	11
Citalopram Hbr	Citalopram Hydrobromide	33	11
Ozempic	Semaglutide	33	suppressed
Alendronate Sodium	Alendronate Sodium	32	suppressed
Mirtazapine	Mirtazapine	32	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	31	suppressed
Carvedilol	Carvedilol	29	suppressed
Clopidogrel	Clopidogrel Bisulfate	29	suppressed
Lorazepam	Lorazepam	29	17
Pravastatin Sodium	Pravastatin Sodium	29	12
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	29	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	27	11
Clonazepam	Clonazepam	25	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	24	suppressed
Glipizide Er	Glipizide	24	suppressed
Irbesartan	Irbesartan	24	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	22	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	20	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	20	suppressed
Memantine Hcl	Memantine Hcl	20	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	19	17
Tizanidine Hcl	Tizanidine Hcl	19	suppressed
Valacyclovir	Valacyclovir Hcl	18	suppressed
Paroxetine Hcl	Paroxetine Hcl	17	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	16	11
Diclofenac Sodium	Diclofenac Sodium	16	suppressed
Glipizide	Glipizide	16	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	16	suppressed
Loperamide	Loperamide Hcl	15	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	15	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	13	suppressed
Incruse Ellipta	Umeclidinium Bromide	13	suppressed
Prednisone	Prednisone	13	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Synthroid	Levothyroxine Sodium	13	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Morphine Sulfate	Morphine Sulfate	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Valsartan	Valsartan	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	11	suppressed
Labetalol Hcl	Labetalol Hcl	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Trospium Chloride	Trospium Chloride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error